Abstract
To determine the incidence of adverse drug reactions (ADRs) associated with ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus. We report interim results of a postmarketing surveillance survey. Japanese physicians recorded ADRs in elderly patients (≥ 65 years old) who were first prescribed with ipragliflozin within 3 months of its launch (April 2014). Incidence of ADRs within 1 year of starting treatment with ipragliflozin. 898 ADRs occurred in 721/7,170 patients (10.06%). Skin complication-, volume depletion-, genital infection-, polyuria/pollakiuria-, urinary tract infection-, and hypoglycemia-related ADRs occurred in 2.23%, 1.90%, 1.45%, 1.32%, 0.77%, and 0.32%, respectively. ADRs were classified as serious in 44 (0.61%) patients. Half of the ADRs occurred within 30 days of starting treatment. There were no cases of Stevens-Johnson syndrome or toxic epidermal necrolysis. Most (92.1%) of the ADRs resolved or improved. Glycated hemoglobin, fasting blood glucose, body weight, and systolic blood pressure decreased by 0.6% (baseline 7.8%), 22.7 mg/dL (baseline 163.0 mg/dL), 2.3 kg (baseline 67.4 kg), and 3.1 mmHg (baseline 133.2 mmHg), respectively, from baseline to treatment discontinuation/last visit. Ipra...Continue Reading
References
May 1, 1994·British Journal of Clinical Pharmacology·N Baber
Feb 14, 2009·The Journal of Nutrition, Health & Aging·J M G A ScholsM G M Olde Rikkert
Jun 29, 2013·Journal of Diabetes and Its Complications·Kristina M JohnssonJames F List
Jul 16, 2013·Journal of Diabetes and Its Complications·Kristina M JohnssonJames F List
Sep 13, 2013·Annals of Internal Medicine·Despoina VasilakouApostolos Tsapas
Jan 8, 2014·Postgraduate Medicine·Lindsay E NicolleKeith Usiskin
Feb 13, 2014·Current Medical Research and Opinion·Paul NyirjesyKeith Usiskin
Apr 16, 2014·Diabetes Research and Clinical Practice·Trisha DunningStephen Colagiuri
Jun 13, 2014·Diabetes, Obesity & Metabolism·A KashiwagiA Utsuno
Oct 29, 2014·Diabetes, Obesity & Metabolism·A KashiwagiE Ueyama
Nov 21, 2014·Journal of Diabetes Investigation·Atsunori KashiwagiItsuro Nagase
Dec 20, 2014·The Lancet. Diabetes & Endocrinology·Simeon I TaylorKristina I Rother
Apr 9, 2015·Expert Opinion on Drug Safety·Daisuke YabeYutaka Seino
Jul 7, 2015·International Journal of Clinical Practice·S A Brunton
Sep 13, 2015·Biochemical Pharmacology·I DardiS A Jabbour
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Sep 30, 2015·Journal of Diabetes Investigation·Hadrien CharvatManami Inoue
Citations
Jul 28, 2016·Expert Opinion on Pharmacotherapy·Hiroshi MaegawaIchiro Nakamura
Aug 2, 2016·Expert Opinion on Pharmacotherapy·Koutaro YokoteHaruko Sugamori
Sep 7, 2016·Expert Opinion on Pharmacotherapy·Hiroyuki ItoMariko Abe
Oct 26, 2018·The Journal of International Medical Research·Toshihiro HigashikawaMasashi Okuro
Mar 7, 2018·Diabetology & Metabolic Syndrome·Hiroki NakajimaHitoshi Ishii
Feb 1, 2019·Journal of Diabetes Investigation·Kazunori UtsunomiyaKohei Kaku
Dec 20, 2019·Therapeutic Advances in Cardiovascular Disease·Takahiro KambaraMasayoshi Ajioka
Feb 2, 2018·Expert Opinion on Pharmacotherapy·Hiroshi MaegawaSatoshi Uno
Jul 28, 2019·Current Medical Research and Opinion·Hiroshi MaegawaSatoshi Uno
Aug 16, 2019·Postgraduate Medicine·Weiping ChenMulan Chen
Sep 14, 2016·Cardiovascular Diabetology·Atsushi TanakaUNKNOWN PROTECT Study Investigators
Aug 28, 2020·Advances in Therapy·Dan LiuHongyan Wu
Jun 24, 2017·Journal of Diabetes Investigation·Takeshi OsonoiYusuke Osonoi
Aug 22, 2017·Endocrine Journal·Soichi TakeishiShodo Takekoshi
May 29, 2018·Endocrine Journal·Takashi NomiyamaUNKNOWN Collaborators of Fukuoka Study of Ipragliflozin (FUSION) trial
Dec 17, 2020·The Journal of Clinical Hypertension·Kenta OkadaKazuomi Kario
Mar 16, 2021·PloS One·Hiroyuki ItoMichiko Togane
Mar 18, 2021·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Ichiro NakamuraSatoshi Uno